Related Experiment Video

Updated: Apr 8, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

925

Mogrol represents a novel leukemia therapeutic, via ERK and STAT3 inhibition

Can Liu1, Yan Zeng2, Long-Hai Dai2

  • 1Beijing University of Agriculture Beijing 102206, China ; National Engineering Laboratory for Industrial Enzymes, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences Tianjin 300308, China ; Key Laboratory of Urban Agriculture (North) of Ministry of Agriculture P. R. China, Beijing University of Agriculture Beijing 102206, China.

American Journal of Cancer Research
|June 24, 2015
PubMed

Insights

Mogrol, a natural compound, effectively inhibits leukemia cell growth by targeting the ERK1/2 and STAT3 pathways. This novel leukemia treatment induces apoptosis and cell cycle arrest, offering a promising alternative to chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Chemotherapy is the primary leukemia treatment but causes adverse effects and drug resistance.
  • Novel therapeutic agents are needed to effectively treat leukemia with fewer side effects.
  • The Raf/MEK/ERK and STAT3 pathways are crucial in leukemia development and represent potential therapeutic targets.

Purpose of the Study:

  • To investigate the anti-cancer activity of mogrol, a biometabolite of mogrosides.
  • To elucidate the mechanism of action of mogrol in K562 leukemia cells.
  • To explore mogrol as a potential novel agent for leukemia treatment.

Main Methods:

  • K562 leukemia cells were treated with mogrol.
  • The effects of mogrol on ERK1/2 and STAT3 pathways were analyzed.
  • Expression levels of p-ERK1/2, p-STAT3, Bcl-2, and p21 were assessed.
  • Apoptosis and cell cycle arrest were evaluated.

Main Results:

  • Mogrol suppressed K562 leukemia cell growth.
  • Mogrol inhibited the ERK1/2 and STAT3 pathways by reducing p-ERK1/2 and p-STAT3 levels.
  • Mogrol induced apoptosis by suppressing Bcl-2 expression.
  • Mogrol promoted G0/G1 cell cycle arrest through enhanced p21 expression.

Conclusions:

  • Mogrol exhibits anti-leukemia effects by inhibiting the ERK1/2 and STAT3 signaling pathways.
  • Mogrol induces apoptosis and cell cycle arrest in leukemia cells.
  • Mogrol represents a promising novel therapeutic candidate for leukemia treatment.
Keywords:
ERK1/2MogrosidesSTAT3apoptosismogrol

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.6K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K